Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNC | P24863 | 5/20 | 0.42 |
| ▸ | CDK8 | P49336 | 5/20 | 0.42 |
| ▸ | SLC22A12 | Q96S37 | 5/20 | 0.37 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.33 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.33 |
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL578334 | 0.86 | ACVR1 (0.48) | CCNCCDK8SLC22A12TGFBR1ACVR1 | |
| SCHEMBL578478 | 0.84 | CCNC (0.45) | CCNCCDK8SLC22A12CYP11B1CYP11B2 | |
| SCHEMBL578539 | 0.83 | CCNC (0.47) | CCNCCDK8SLC22A12CYP11B1CYP11B2 | |
| SCHEMBL578747 | 0.80 | SLC22A12 (0.46) | CCNCCDK8SLC22A12SMN1; SMN2 | |
| SCHEMBL578953 | 0.79 | SLC22A12 (0.45) | CCNCCDK8SLC22A12SMN1; SMN2 | |
| SCHEMBL578441 | 0.79 | CYP11B1 (0.45) | CCNCCDK8SLC22A12CYP11B1CYP11B2 | |
| SCHEMBL578413 | 0.78 | SLC22A12 (0.43) | CCNCCDK8SLC22A12SMN1; SMN2 | |
| SCHEMBL27885037 | 0.77 | CYP11B2 (0.52) | CCNCCDK8CYP11B1CYP11B2CYP46A1 | |
| SCHEMBL578517 | 0.76 | CCNC (0.44) | CCNCCDK8SLC22A12SMN1; SMN2 | |
| SCHEMBL578667 | 0.76 | CCNC (0.46) | CCNCCDK8SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2418203-B1 | CYCLIC COMPOUND HAVING SUBSTITUTED PHENYL GROUP | DAIICHI SANKYO CO LTD (JP) | 2013-12-11 | — | — | EP | disclosed |
| US-8410273-B2 | Cyclic compound having substituted phenyl group | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-04-02 | — | — | US | disclosed |
| US-20120040936-A1 | CYCLIC COMPOUND HAVING SUBSTITUTED PHENYL GROUP | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-02-16 | — | — | US | disclosed |
| EP-2418203-A1 | CYCLIC COMPOUND HAVING SUBSTITUTED PHENYL GROUP | Daiichi Sankyo Company, Limited (JP) | 2012-02-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040936-A1 | CYCLIC COMPOUND HAVING SUBSTITUTED PHENYL GROUP | BMP2, BMP4, BMP6 | CCNC 1592/4885CDK8 2959/4885SLC22A12 1300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.